Hualan Biological Engineering Stock Price

Hualan Biological Engineering Inc., a biopharmaceutical company, researches, develops, produces, and commercializes blood products, vaccines, and recombinant proteins in China and internationally. The company offers blood products under the Hualan brand comprising human albumin, intravenous human immunoglobulin, human immunoglobulin, tetanus human immunoglobulin, hepatitis B human immunoglobulin, rabies immunoglobulin, human prothrombin complex, human coagulation factor VIII, human fibrinogen, freeze-dried human fibrin glue for surgery, and human fibrin adhesives. It also provides vaccines consisting of quadrivalent and split influenza virus vaccines, influenza A (H1N1) split vaccines, ACYW135 group meningococcal polysaccharide vaccines, recombinant hepatitis B vaccines, group A and C meningococcal polysaccharide vaccines, freeze-dried human rabies vaccines, adsorbed tetanus vaccines, and multiple vaccine products; and biological products. In addition, the company is involved in plasma collection; poultry breeding for research and development; engineering technology research and experimental development; inspection and testing; biotechnology development; and medical services. Hualan Biological Engineering Inc. was founded in 1992 and is headquartered in Xinxiang City, the People’s Republic of China.